HDL2 Lipoproteins

Low-density subclass of the high-density lipoproteins, with particle sizes between 8 to 13 nm.
Also Known As:
Lipoproteins, HDL2; HDL-2; HDL2 Lipoprotein; High Density Lipoprotein HDL2; Lipoprotein HDL2; HDL 2; HDL2, Lipoprotein; High Density Lipoprotein 2; Lipoprotein, HDL2; High Density Lipoprotein-2
Networked: 50 relevant articles (2 outcomes, 3 trials/studies)

Relationship Network

Bio-Agent Context: Research Results


1. McGinty, Ann: 3 articles (02/2013 - 01/2013)
2. Young, Ian S: 3 articles (02/2013 - 01/2013)
3. McEneny, Jane: 3 articles (02/2013 - 01/2013)
4. McMaster, Cyril: 2 articles (02/2013 - 01/2013)
5. Wade, Lauren: 2 articles (02/2013 - 01/2013)
6. Patsch, J R: 2 articles (10/2004 - 06/2001)
7. Ebenbichler, C F: 2 articles (10/2004 - 06/2001)
8. Kaser, S: 2 articles (10/2004 - 06/2001)
9. Sandhofer, A: 2 articles (10/2004 - 06/2001)
10. Takahashi, Eiko: 1 article (11/2014)

Related Diseases

1. Dyslipidemias (Dyslipidemia)
06/01/2002 - "A form of dyslipidemia, the atherogenic lipoprotein profile, that consists of elevated intermediate-density lipoprotein (IDL), triglycerides (TGs), dense LDL and dense very low density lipoprotein (VLDL), and low high density lipoprotein-2, occurs in 40% to 50% of patients with coronary artery disease (CAD). "
05/01/1999 - "Insulin resistance is associated with dyslipoproteinemia characterized by increased serum triglycerides, reduced high-density lipoprotein 2 (HDL2) cholesterol, and increased small, dense low-density lipoprotein (LDL) subfraction particles. "
11/01/1995 - "Obesity, insulin resistance (IR) with hyperinsulinemia, and a dyslipoproteinemia characterized by reduced high-density lipoprotein 2 (HDL2) cholesterol and elevated levels of small, dense low-density lipoprotein (LDL) particles are risk factors for coronary artery disease (CAD). "
09/01/2002 - "These data indicate that in diabetic patients, extended-release niacin (1) is effective for separately treating diabetic dyslipidemias associated with abnormal LDL size, HDL-2, and Lp(a) independently of glycated hemoglobin levels; (2) must be used with modern and aggressive oral hypoglycemic agents or insulin treatment; and (3) is a major drug for the treatment of diabetic dyslipidemias because of its broad spectrum of effectiveness for the ALP and Lp(a)."
07/01/2003 - "Excessive weight gain in a subset of intensively treated Diabetes Control and Complications Trial (DCCT) subjects was associated with higher waist to hip ratio; higher triglyceride (TG), low-density lipoprotein (LDL) cholesterol, and apolipoprotein B (ApoB) in the presence of small-dense LDL; and decreased high-density lipoprotein 2 cholesterol (HDL2-C), suggesting that weight gain in these subjects resulted in higher intraabdominal fat (IAF), and an atherosclerotic dyslipidemia mediated through hepatic lipase activity (HL). "
2. Weight Loss (Weight Reduction)
3. Spinocerebellar Ataxias (Spinocerebellar Ataxia)
4. Progressive Myoclonic Epilepsies (Progressive Myoclonic Epilepsy)
5. Neurodegenerative Diseases (Neurodegenerative Disease)

Related Drugs and Biologics

1. Lipoproteins (Lipoprotein)
2. Apolipoproteins B (ApoB)
3. 1-Alkyl-2-acetylglycerophosphocholine Esterase (PAF Acetylhydrolase)
4. Niacin (Nicotinic Acid)
5. Insulin (Novolin)
6. Hypoglycemic Agents (Hypoglycemics)
7. Hemoglobins (Hemoglobin)
8. ruberythric acid (AlP)
9. Cholesterol
10. HDL3 Lipoproteins

Related Therapies and Procedures

1. Bariatric Surgery
2. Transplants (Transplant)
3. Transplantation (Transplant Recipients)
4. Ligation
5. Renal Dialysis (Hemodialysis)